The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
By 2030, What Market Size Is The Cancer Immunotherapy Market Expected To Reach Based On Its 2026 Value?
The cancer immunotherapy market size has experienced significant expansion recently. It is projected to increase from $124.09 billion in 2025 to $137.99 billion in 2026, achieving a compound annual growth rate (CAGR) of 11.2%. The historical development of this market is attributable to breakthroughs in tumor immunology, a rising global incidence of cancer, the early success of monoclonal antibodies, increased oncology R&D funding, and regulatory approvals for checkpoint inhibitors.
The cancer immunotherapy market is anticipated to experience significant expansion in the coming years. Its valuation is projected to reach $210.39 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 11.1%. Factors contributing to this growth during the projection period include the increasing uptake of CAR T-cell therapies, the broadening scope into solid tumor treatments, heightened investment in cancer vaccines, the escalating need for targeted combination therapies, and favorable reimbursement frameworks for immunotherapy. Key trends expected within this forecast timeframe encompass the swift integration of immune checkpoint inhibitors, the expanding application of combination immunotherapy protocols, the proliferation of cell-based cancer treatments, an increased emphasis on individualized immunotherapy, and a rising volume of oncology clinical trials.
Access Your Free Sample Report For In-Depth Market Analysis:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6768&type=smp
What Factors Are Contributing To The Growth Of The Cancer Immunotherapy Market?
An anticipated increase in cancer cases is poised to drive the growth of the cancer immunotherapy market. Globally, several elements contribute to this rise in cancer occurrences, such as tobacco use, alcohol consumption, obesity, inactive lifestyles, and various environmental influences. The increasing number of cancer cases is predicted to elevate the need for cancer immunotherapies, particularly as patients show a growing inclination to invest in medical interventions offering improved recovery prospects and reduced discomfort. For example, in July 2024, projections from Cancer Research UK, a UK-based cancer charity, indicate that cancer incidence rates in the United Kingdom are forecast to rise for the majority of cancer types between 2023-2025 and 2038-2040. These increases are expected to vary significantly, from less than 1% for breast cancer up to 50% for eye cancer. Conversely, a few cancer types are anticipated to show a decrease, with reductions ranging from 2% for lung cancer to 27% for mesothelioma. Consequently, the growing prevalence of cancer is set to enhance the demand for cancer immunotherapy over the forecast period.
How Is The Cancer Immunotherapy Market Broken Down By Segment Categories?
The cancer immunotherapy market covered in this report is segmented –
1) By Product: Monoclonal Antibodies, Checkpoint Inhibitors, Immunomodulators, Vaccines, Cell Therapy
2) By Application: Lung Cancer, Breast Cancer, Colorectal Cancer, Melanoma, Prostate Cancer, Multiple Myeloma
3) By End User: Hospitals, Cancer Research Centers, Clinics
Subsegments:
1) By Monoclonal Antibodies: Chimeric Monoclonal Antibodies, Humanized Monoclonal Antibodies, Fully Human Monoclonal Antibodies
2) By Checkpoint Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4 Inhibitors
3) By Immunomodulators: Cytokines, Oncolytic Viruses, Toll-Like Receptor (TLR) Agonists
4) By Vaccines: Therapeutic Cancer Vaccines
5) By Cell Therapy: CAR T-Cell Therapy, TCR Therapy, Natural Killer (NK) Cell Therapy
What Market Trends Are Affecting The Cancer Immunotherapy Market?
Major companies operating in the cancer immunotherapy market are concentrating on developing innovative solutions, such as PD-1 immunotherapies, to extend the availability of advanced immune-based treatment options for patients suffering from hard-to-treat cancers. A PD-1 immunotherapy is an immune checkpoint-targeting treatment designed to stimulate antitumor immune activity by blocking interactions within the programmed death-1 pathway. For instance, in August 2025, Intas Pharmaceuticals, an India-based pharmaceutical firm specializing in oncology and biologics, introduced HETRONIFLY (Serplulimab). This therapy stands as the first programmed death-1 inhibitor approved globally for extensive-stage small cell lung cancer, employing a dual mechanism that targets PD-L1 and PD-L2 with strong receptor internalization to enhance immune engagement. Its proven survival benefit and significantly reduced cost compared with existing immunotherapies emphasize its clinical worth and broaden patient access to advanced cancer treatment in India.
Which Players Are Present In The Cancer Immunotherapy Market Space?
Major companies operating in the cancer immunotherapy market are Amgen Inc., AstraZeneca PLC, F. Hoffmann-La Roche Ltd, Bayer AG, Eli Lilly and Company, Adaptive Biotechnologies Corp., Argos Therapeutics Inc., Bristol-Myers Squibb Company, Cell Medica Limited, Cellular Biomedicine Group Inc., Gilead Sciences Inc., Gradalis Inc., Immatics Biotechnologies GmbH, Iovance Biotherapeutics Inc., Juno Therapeutics LLC, MacroGenics Inc., Merck & Co. Inc., Neon Therapeutics Inc., Neovii Biotech GmbH, Novartis International AG, Pfizer Inc., Regeneron Pharmaceuticals Inc., Roche Holding AG, Targovax ASA, Tessa Therapeutics Pte Ltd., TILT Biotherapeutics Ltd., Turnstone Biologics Corp., Xencor Inc., Kura Oncology Inc.
Get The Full Cancer Immunotherapy Market Report:
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Which Region Is The Leading Market For The Cancer Immunotherapy Market?
North America was the largest region in the cancer immunotherapy market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer immunotherapy market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Cancer Immunotherapy Market Report For Competitive Insights:
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Browse Through More Reports Similar to the Global Cancer Immunotherapy Market 2026, By The Business Research Company
Cancer Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cancer-immunotherapy-global-market-report
Cellulars Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/cellulars-immunotherapy-global-market-report
Allergy Immunotherapy Market Report 2026
https://www.thebusinessresearchcompany.com/report/allergy-immunotherapy-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model